AdaptHealth vs Viemed Healthcare
AHCO and VMD side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AHCO and VMD compare
AdaptHealth is the larger company, worth 3.0 times as much as Viemed Healthcare ($1.0B against $349M).
Viemed Healthcare grew revenue faster over the last twelve months (21.8% versus 20.7% for AdaptHealth).
Viemed Healthcare keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with −11.4% at AdaptHealth.
Viemed Healthcare scores higher on the StockData Score (18 against 7 for AdaptHealth), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AHCO | VMD |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $349M |
| Share price | $7.66 | $9.17 |
| Change, 1 year | −17.8% | 40.0% |
| Change, 5 years | −66.7% | 68.3% |
| Beta (5Y) | 0.72 | 0.58 |
| Employees | 11K | 1,382 |
| StockData Score | ||
| Total score | 7 | 18 (better) |
| Valuation score | 3 | 5 (better) |
| Growth score | 1 | 5 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 24.1× |
| P/S | 0.3× (better) | 1.1× |
| P/B | 0.9× (better) | 2.3× |
| EV/EBITDA | 24.2× | 8.6× (better) |
| P/FCF | 12.7× (better) | 16.3× |
| PEG | – | 0.75 |
| FCF yield | 7.8% (better) | 6.1% |
| Fair value | $19.52 | $11.52 |
| Margin of safety | 60.8% (better) | 20.4% |
| Growth | ||
| Revenue growth (TTM) | 20.7% | 21.8% (better) |
| Revenue growth, 5Y average | 25.2% (better) | 15.5% |
| Net income growth (TTM) | −595% | 14.8% (better) |
| EPS growth (TTM) | −638% | 15.2% (better) |
| EPS growth, 5Y average | – | −13.9% |
| Profitability | ||
| Gross margin | 15.7% | 57.4% (better) |
| Operating margin | −8.9% | 7.8% (better) |
| Net margin | −11.4% | 5.0% (better) |
| FCF margin | 2.3% | 6.9% (better) |
| Return on equity | −28.6% | 11.0% (better) |
| Return on invested capital | −7.9% | 11.8% (better) |
| Financial health | ||
| Debt / equity | 1.54 | 0.03 (better) |
| Net debt / EBITDA | 15.53 (better) | −0.12 |
| Current ratio | 1.13 | 1.25 (better) |
| Altman Z-score | 0.53 | 6.47 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 2.2% |
| Shareholder yield | 0.00% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 104% | 71.3% |
| Held by insiders | 14.7% | 15.4% |
| Insider net buying, 12 months | $49.1M (better) | −$1.6M |
| Short interest, % of float | 9.4% | 4.7% |
Go deeper
- AHCO stock overview
- AHCO income statement
- AHCO valuation and score
- VMD stock overview
- VMD income statement
- VMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.